Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Früh

Showing results (41-50 of 92) with videos related to

Pageof 10
Sort By:
Cancer Chemotherapy and Pharmacology|January 27, 2019
Prognostic impact of polypharmacy and drug interactions in patients with advanced cancerAlexander Hoemme, Holger Barth, Manuel Haschke, et al.
Clinical Lung Cancer|May 29, 2012
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08)Martin Früh, Richard Cathomas, Marco Siano, et al.
Plos One|September 17, 2013
EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancerFlorent Baty, Sacha Rothschild, Martin Früh, et al.
Cancer Management and Research|December 7, 2018
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatmentStefan Diem, Mirjam Fässler, Omar Hasan Ali, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2025
Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19)Alfredo Addeo, Daniel Dietrich, Nicolas Mach, et al.
Frontiers in Oncology|September 25, 2020
Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer PatientsChristian Britschgi, Alfredo Addeo, Markus Rechsteiner, et al.
JTO Clinical and Research Reports|December 5, 2022
Viral Mimicry Response Is Associated With Clinical Outcome in Pleural MesotheliomaSuna Sun, Weihong Qi, Hubert Rehrauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2008
Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancerMartin Früh, Estelle Rolland, Jean-Pierre Pignon, et al.
Non-Coding RNA|June 20, 2019
miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and SurgeryJelena Kresoja-Rakic, Adam Szpechcinski, Michaela B Kirschner, et al.
Lung Cancer (Amsterdam, Netherlands)|May 2, 2021
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trialPatrizia Froesch, Michael Mark, Sacha I Rothschild, et al.
Pageof 10

Showing results (41-50 of 92) with videos related to

Sort By:
Pageof 10
Cancer Chemotherapy and Pharmacology|January 27, 2019
Prognostic impact of polypharmacy and drug interactions in patients with advanced cancerAlexander Hoemme, Holger Barth, Manuel Haschke, et al.
Clinical Lung Cancer|May 29, 2012
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08)Martin Früh, Richard Cathomas, Marco Siano, et al.
Plos One|September 17, 2013
EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancerFlorent Baty, Sacha Rothschild, Martin Früh, et al.
Cancer Management and Research|December 7, 2018
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatmentStefan Diem, Mirjam Fässler, Omar Hasan Ali, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2025
Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19)Alfredo Addeo, Daniel Dietrich, Nicolas Mach, et al.
Frontiers in Oncology|September 25, 2020
Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer PatientsChristian Britschgi, Alfredo Addeo, Markus Rechsteiner, et al.
JTO Clinical and Research Reports|December 5, 2022
Viral Mimicry Response Is Associated With Clinical Outcome in Pleural MesotheliomaSuna Sun, Weihong Qi, Hubert Rehrauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2008
Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancerMartin Früh, Estelle Rolland, Jean-Pierre Pignon, et al.
Non-Coding RNA|June 20, 2019
miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and SurgeryJelena Kresoja-Rakic, Adam Szpechcinski, Michaela B Kirschner, et al.
Lung Cancer (Amsterdam, Netherlands)|May 2, 2021
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trialPatrizia Froesch, Michael Mark, Sacha I Rothschild, et al.
Pageof 10